Thompson Siegel & Walmsley LLC Takes Position in Myomo, Inc. (NYSEAMERICAN:MYO)

Thompson Siegel & Walmsley LLC acquired a new stake in Myomo, Inc. (NYSEAMERICAN:MYOFree Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 200,000 shares of the company’s stock, valued at approximately $1,288,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MYO. Barclays PLC bought a new position in Myomo in the third quarter valued at approximately $36,000. Jane Street Group LLC bought a new position in Myomo in the third quarter valued at approximately $65,000. XTX Topco Ltd bought a new position in Myomo in the third quarter valued at approximately $149,000. Thompson Davis & CO. Inc. bought a new position in Myomo in the fourth quarter valued at approximately $181,000. Finally, Calamos Advisors LLC bought a new position in Myomo in the fourth quarter valued at approximately $189,000. 44.99% of the stock is owned by institutional investors.

Myomo Trading Up 2.4 %

Shares of NYSEAMERICAN:MYO opened at $5.19 on Friday. Myomo, Inc. has a 12 month low of $2.51 and a 12 month high of $7.17. The firm has a market cap of $157.00 million, a P/E ratio of -22.57 and a beta of 1.68.

Insider Buying and Selling

In other Myomo news, insider Micah Mitchell sold 48,000 shares of Myomo stock in a transaction on Friday, March 14th. The shares were sold at an average price of $5.16, for a total value of $247,680.00. Following the sale, the insider now directly owns 140,572 shares in the company, valued at approximately $725,351.52. The trade was a 25.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas F. Kirk purchased 7,400 shares of the stock in a transaction on Thursday, March 13th. The stock was acquired at an average price of $5.00 per share, for a total transaction of $37,000.00. Following the completion of the purchase, the director now directly owns 255,933 shares in the company, valued at approximately $1,279,665. The trade was a 2.98 % increase in their position. The disclosure for this purchase can be found here. 4.54% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on MYO shares. HC Wainwright lifted their price target on shares of Myomo from $7.50 to $9.50 and gave the stock a “buy” rating in a research report on Wednesday. Alliance Global Partners reissued a “buy” rating on shares of Myomo in a research report on Tuesday. Finally, Craig Hallum lifted their price target on shares of Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $9.25.

View Our Latest Research Report on MYO

Myomo Company Profile

(Free Report)

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.

Read More

Want to see what other hedge funds are holding MYO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myomo, Inc. (NYSEAMERICAN:MYOFree Report).

Institutional Ownership by Quarter for Myomo (NYSEAMERICAN:MYO)

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.